Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel‐Wahab, Ross L. Levine, Ann Mullally et al.|Blood|2009Cited by 718
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Blood|2006Cited by 468
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M. Stein, Martin S. Tallman, Guillermo Garcia‐Manero et al.|Blood|2018Cited by 457